The place of inhibitor-protected penicillins in the treatment of lower respiratory tract infections
https://doi.org/10.21518/2079-701X-2015-16-50-55
Abstract
The main nosological forms of lower respiratory tract infections are infectious exacerbation of chronic bronchitis, chronic obstructive pulmonary disease (COPD) and community-acquired pneumonia (CAP). The relevant antibacterial drugs in the above-mentioned diseases are b-lactam antibiotics (aminopenicillins including inhibitor-protected penicillins, II-III generation cephalosporins), macrolides, respiratory fluoroquinolones. Inhibitor-protected penicillins, macrolides, and respiratory fluoroquinolones are similar in their clinical and microbiological efficacy. When choosing the antibacterial drug, it is necessary to take into account the clinical case, in particular, the severity of acute exacerbations of chronic bronchitis, COPD and CAP, poor response factors, risk of antibiotic resistance, ease of dosing regimens, safety and tolerability of the antibacterial drug.
About the Author
O. A. Tsvetkova
First Moscow State Medical University named after I.M. Sechenov
Russian Federation
Russian Federation
References
1. Гучев И.А., Козлов Р.С. Безопасность и эффективность различных лекарственных форм амоксициллина/клавулановой кислоты при инфекциях нижних дыхательных путей у взрослых: открытое проспективное рандомизированное исследование. Пульмонология, 2008, 2: 73-80.
2. Дворецкий Л.И., Александрова М.А. Критический анализ консенсусных практических рекомендаций IDSA и ATS по лечению вне-больничной пневмонии 2007 года. Consilium Medicum. Антимикробная терапия, 2008, 10(1).
3. Козлов Р.С., Сивая О.В., Шпынев К.В. и др. Антибиотикорезистентность Streptococcus pneumoniae в России в 1999-2005 гг: результаты многоцентровых проспективных исследований ПеГАС-I и ПеГАС-II. Клин Микробиол Антимикр Химиотер., 2006, 8:1: 33-47.
4. Практическое руководство по антиинфекционной химиотерапии. Под редакцией Страчунского Л.С., Белоусова Ю.Б., Козлова С.Н. М.: Боргес, 2002: 33-38.
5. Синопальников А.И., Романовских А.Г. Инфекционные обострения хронической обструктивной болезни легких. Соnsiliummedicum, 2006, 8(1).
6. Чучалин А.Г, Синопальников А.И., Страчунский Л.С. и соавт. Внебольничная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике. КМАХ, 2006, 8: 54-86.
7. Чучалин А.Г. и др. Внебольничная пневмония у взрослых. Практические рекомендации по диагностике, лечению и профилактике. М., 2010.
8. Abraham EP, Chain E. An enzyme from bacteria able to destroy penicillin. Nature, 1940, 373: 837.
9. Anzueto A, Fisher CL Jr, Busman T, Olson CA. Comparison of the efficacy of extended-release clarithromycin tablets and amoxicillin/ clavulanate tablets in the treatment of acute exacerbation of chronic bronchitis. Clin Ther, 2001, 23: 72-86, 4.
10. Brad Spellberg Dr. William H. Stewart: Mistaken or Maligned? Clinical Infectious Diseases, 2008, 47: 294-294.
11. File T, Schlemmer B, Garau J, Lode H, Lynch S, Young C. Gemifloxacin versus amoxicillin/cla-vulanate in the treatment of acute exacerbations of chronic bronchitis. The 070 Clinical Study group. J Chemother, 2000, 12: 314-32.
12. Kahn JB, Wiesinger A, Olson WH et al. Levofloxacin vs ceftriaxone sodium and erytro-mycin in the treatment of patients with community-acquired pneumonia at high risk of mortality. Abstracts of 7th International Symposium on New Ouinolones. Edinburg, UK, 2001, 45.
13. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD et al. IDSA/ATS Guidelines for CAP in adults. Clinical Infectious Diseases, 2007, 44 (Suppl.2): S27-72.
14. Martinot JB, Carr WD, Cullen S et al. A comparative study of clarithromycin modified release and amoxicillin/clavulanic acid in the treatment of acute exacerbation of chronic bronchitis. Adv Ther, 2001, 18: 1-11.
15. Martinez JA, Horcajada JP, Almela M еt al. Addition of macrolide to a beta-lactam-basee empirical antibiotic regimen is associated with lower inhospitality mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis, 2003, 36: 389-95.
16. Niederman MS, Mandell LA, Anzueto A et al. Guidelines for management of adults with community-acquired pneumonia. Diagnosos, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med, 2001, 163: 1730-1754.
17. Norrby SR, Petermann W, Willcox PA, et al. A comparative study of levofloxacin and ceftriax-one in the treatment of hospitalized patients with pneumonia. Scand J Infect Dis, 1998, 30: 397-404.19.
18. Schaberg T, Ballin I, Huchon G et al. A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis. J Int Med Res, 2001, 29: 314-28.
19. Starakis I, Gogos CA, Bassaris H. Five-day moxi-floxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis. Int J Antimicrob Agents, 2004, 23: 129-37.
20. Yandiola PP, Capelastegui A, Ouintana J, Diez R, Gorordo I, Bilbao A, Zalacain R, Menendez R, Torres A. Prospective comparison of severity scores for predicting clinically relevant outcomes for patients hospitalized with community-acquired pneumonia. Chest, 2009, 135(6).
Review
For citations:
Tsvetkova OA. The place of inhibitor-protected penicillins in the treatment of lower respiratory tract infections. Meditsinskiy sovet = Medical Council. 2015;(16):50-55. (In Russ.) https://doi.org/10.21518/2079-701X-2015-16-50-55
Views:
403
Email this article 